Advertisement
Organisation › Details
Shire Ltd. (LSE: SHP, NASDAQ: SHPGY)
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results. *
Start | 2008-05-23 reorganised | |
Group | Takeda (Group) | |
Predecessor | Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ) | |
Region | Dublin | |
Country | Ireland, Republic of | |
City | n. a. Dublin | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: | ||
Record changed: 2020-07-03 |
Advertisement
More documents for Takeda (Group)
- [1] T-Curx GmbH. (8/28/23). "Press Release: T-Curx GmbH Announces Appointment of Two Industry Leaders to Its Board of Directors"....
- [2] Fresenius Medical Care AG & Co. KGaA. (12/5/22). "Press Release: Helen Giza to Take Over as Chief Executive Officer of Fresenius Medical Care"....
- [3] VectorY B.V.. (11/8/22). "Press Release: VectorY Appoints Sander van Deventer as CEO and Makes Key Appointments to Its Leadership Team". Amsterdam....
- [4] Heidelberg Pharma AG. (9/9/22). "Press Release: Heidelberg Pharma Announces Conclusion of License Agreement with Partner Takeda To Develop an Antibody Targeted Amanitin Conjugate". Ladenburg....
- [5] Takeda Pharmaceutical Co. Ltd.. (2/3/22). "Press Release: Takeda Announces Strategic Leadership Changes to Help Drive Continued Growth and Competitiveness in Global Marketplace". Osaka & Cambridge, MA....
- [6] Takeda Pharmaceutical Co. Ltd.. (1/10/22). "Press Release: Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (gd) T Cell Engager Therapies Targeting Solid Tumors". Osaka & London....
- [7] Integra Thepeutics S.L.. (12/2/21). "Press Release: Integra Tx Secures €4.5 Million in Funding from Advent France Biotechnology, Invivo Capital and Takeda Ventures". Barcelona....
- [8] GammaDelta Therapeutics Ltd.. (10/27/21). "Press Release: Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic gdT Cell Therapies Addressing Solid Tumors". Osaka & London....
- [9] Panekès Partners SGR S.p.A.. (9/27/21). "Press Release: Panakès Partners Appoints Dr. Rob Woodman as Partner to Lead Biotech Investment". Milan....
- [10] Transine Therapeutics Ltd.. (6/2/21). "Press Release: Transine Therapeutics Closes Extended Seed Funding of £9.1 Million Co-led by Takeda Ventures, Inc. and the Dementia Discovery Fund to Advance Its Novel Class of Therapeutic RNAs". Cambridge....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top